N,N-Dimethylethylenediamine → 4-[5-(5-Diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-N-(2-dimethylamino-ethyl)-benzamide
반응식
[CH2:1]([N:3]([CH2:6][C:7]1[S:11][C:10]([C:12]2[O:16][N:15]=[C:14]([C:17]3[CH:25]=[CH:24][C:20]([C:21](O)=[O:22])=[CH:19][CH:18]=3)[N:13]=2)=[CH:9][C:8]=1[CH3:26])[CH2:4][CH3:5])[CH3:2].[CH3:27][N:28]([CH3:32])[CH2:29][CH2:30][NH2:31]>>[CH2:1]([N:3]([CH2:6][C:7]1[S:11][C:10]([C:12]2[O:16][N:15]=[C:14]([C:17]3[CH:25]=[CH:24][C:20]([C:21]([NH:31][CH2:30][CH2:29][N:28]([CH3:32])[CH3:27])=[O:22])=[CH:19][CH:18]=3)[N:13]=2)=[CH:9][C:8]=1[CH3:26])[CH2:4][CH3:5])[CH3:2]참가 물질
3
실험 절차
The title compound (9 mg) is prepared in analogy to Example 189 step b) starting from 4-[5-(5-diethylaminomethyl-4-methyl-thiophen-2-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (37 mg, 100 μmol) and N1,N1-dimethyl-ethane-1,2-diamine (10 mg, 110 μmol); LC-MS: tR=0.42 min; [M+1]+=442.23. 1H NMR (CDCl3): δ1.11 (t, J=7.0 Hz, 6H), 2.26 (s, 3H), 2.32 (s, 6H), 2.58 (t, J=6.0 Hz, 2H), 2.64 (q, J=7.0 Hz, 4H), 3.55-3.62 (m, 2H), 3.73 (s, 2H), 6.95 (t br, J=4.8 Hz, 1H), 7.68 (s, 1H), 7.92-7.96 (m, 2H), 8.21-8.25 (m, 2H).